- Previous Close
4.3200 - Open
4.3000 - Bid 4.1300 x 2700
- Ask 4.1600 x 2700
- Day's Range
4.1400 - 4.3500 - 52 Week Range
1.6400 - 5.3400 - Volume
7,633,190 - Avg. Volume
9,034,467 - Market Cap (intraday)
2.502B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.31
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
View More
Performance Overview: GERN
Trailing total returns as of 10/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
View MoreValuation Measures
Market Cap
2.60B
Enterprise Value
2.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.91k
Price/Book (mrq)
8.49
Enterprise Value/Revenue
1.70k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.87%
Return on Equity (ttm)
-72.56%
Revenue (ttm)
1.37M
Net Income Avi to Common (ttm)
-219.55M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
362.73M
Total Debt/Equity (mrq)
28.38%
Levered Free Cash Flow (ttm)
-126.95M
Research Analysis: GERN
View MoreCompany Insights: GERN
GERN does not have Company Insights